Ac immune's targeted anti-ptau active immunotherapy for alzheimer's disease advances into phase 2b trial

Ac immune's targeted anti-ptau active immunotherapy for alzheimer's disease advances into phase 2b trial potentially registration-enabling phase 2b study (retain) will evaluate the effect of aci-35.030 on cognition and tau pathology in approximately 500 participants with preclinical alzheimer's disease (ad) anti-ptau active immunotherapy being designed to potentially prevent or reduce cognitive decline could address need of over 315 million people globally1 with preclinical ad ac immune to receive approximately chf 40 million in total milestone payments under terms of the licensing agreement, following trial initiation and enrollment milestone lausanne, switzerland, december 15, 2023 – ac immune sa (nasdaq: aciu), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that its development partner has programmed the launch of a phase 2b clinical study to evaluate aci-35.030 (jnj-64042056) in patients with preclinical alzheimer's disease (ad), those individuals not yet showing symptoms. aci-35.030 is an investigational targeted active immunotherapy, selective for pathological phosphorylated tau (ptau).
ACIU Ratings Summary
ACIU Quant Ranking